Schedule Update - effective 1 September 2009 (text extract)

This is the text extract for Schedule Update - effective 1 September 2009, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 September 2009 Section H cumulative for August and September 2009

Contents

Summary of PHARMAC decisions effective 1 September 2009 ...................... 3 Nicotine replacement therapy – available on prescription ............................. 5 Betaloc CR –removal of endorsement and subsidy reduction ........................ 5 Clopixol tablets – new listing......................................................................... 6 Insulin syringes and needles – new listings.................................................... 6 Cyclosporin A – removal of Special Authority ................................................ 6 Azithromycin Special Authority amendment ................................................. 6 Pilocarpine oral liquid standard formulae...................................................... 7 Bromocriptine mesylate new listing and brand change ................................. 7 Tri-phasic oral contraceptives ........................................................................ 7 Panteston capsule brand change................................................................... 8 Kenacort-A injection ...................................................................................... 8 Anastrozole-DP restriction removal ............................................................... 8 Tender News .................................................................................................. 9 Looking Forward ......................................................................................... 10 Sole Subsidised Supply products cumulative to September 2009................ 11 New Listings ................................................................................................ 17 Changes to Restrictions ............................................................................... 18 Changes to Subsidy and Manufacturer’s Price............................................. 23 Changes to Sole Subsidised Supply ............................................................. 24 Delisted Items ............................................................................................. 25 Items to be Delisted .................................................................................... 27 Section H changes to Part II ........................................................................ 29 Section H changes to Part IV ....................................................................... 33 Index ........................................................................................................... 34

Summary of PharmaC decisions

effeCtive 1 SePtember 2009 New listings (page 17) • Insulin pen needles (SC Profi-Fine) 29 g x 12.7 mm, 31 g x 5 mm and 31 g x 8 mm – maximum of 100 dev per prescription • Insulin syringes, disposable with attached needle (DM Ject) syringe 0.3 ml with 29 g x 12.7 mm needle, syringe 0.3 ml with 31 g x 8 mm needle, syringe 0.5 ml with 29 g x 12.7 mm needle, syringe 0.5 ml with 31 g x 8 mm needle, syringe 1 ml with 29 g x 12.7 mm needle, and syringe 1 ml with 31 g x 8 mm needle – maximum of 100 dev per prescription • Clopidogrel (Arrow-Clopidogrel) tab 75 mg – Special Authority – Retail pharmacy • Isotretinoin (Oratane) cap 10 mg and 20 mg – Special Authority – Retail pharmacy • Testosterone undecanoate (Andriol Testocaps) cap 40 mg – Retail pharmacySpecialist • Bromocriptine mesylate (Apo-Bromocriptine) cap 5 mg – Section 29 • Zuclopenthixol hydrochloride (Clopixol) tab 10 mg Changes to restrictions (pages 18 to 22) • Ketone blood beta-ketone electrodes (Optium Blood Ketone Test Strips) test strip – addition of subsidy by endorsement • Metoprolol succinate (Betaloc CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg – removal of additional subsidy by endorsement • Nicotine (Habitrol) patch 7 mg, 14 mg and 21 mg – maximum of 28 patch per dispensing and 56 patch per prescription – subsidised on prescription and Quit Card • Nicotine (Habitrol) lozenge 1 mg and 2 mg – maximum of 216 loz per dispensing and 432 loz per prescription – subsidised on prescription and Quit Card • Nicotine (Habitrol and Nicotinell) gum 2 mg (fruit and mint) and 4 mg (fruit and mint) – maximum of 384 piece per dispensing and 768 piece per prescription – subsidised on prescription and Quit Card • Goserelin acetate (Zoladex) inj 3.6 mg and 10.8 mg – removal of Special Authority criteria • Azithromycin (Arrow-Azithromycin) tab 500 mg – endorsement waived by Special Authority • Entecavir (Baraclude) tab 0.5 mg – amended Special Authority criteria • Tranylcypromine sulphate (Parnate S29) tab 10 mg – removal of Section 29 • Anastrozole-DP (DP-Anastrozole) tab 1 mg – removal of subsidy by endorsement

Summary of PharmaC decisions – effective 1 September 2009 (continued) • Cyclosporin A (Neoral) cap 25 mg , 50 mg and 100 mg, and oral liq 100 mg per ml – removal of Special Authority criteria • Pilocarpine oral liquid – amended standard formulae Decreased subsidy (page 23) • Insulin pen needles (B-D Micro-Fine) 31 g x 5 mm • Clopidogrel (Apo-Clopidogrel and Plavix) tab 75 mg • Metoprolol succinate (Betaloc CR) tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg • Vinorelbine (Baxter) inj 1 mg for ECP • Fluorometholone (Flucon) eye drops 0.1% increased subsidy (page 23) • Povidone iodine (Betadine Skin Prep) skin preparation, povidone iodine 10% with 30% alcohol • Danazol cap 100 mg (D-Zol and Azol) and cap 200 mg (D-Zol) • Betahistine dihydrochloride (Vergo 16) tab 16 mg • Flutamide (Flutamin) tab 250 mg • Oral feed 1 kcal/ml (Fortimel) liquid, 200 ml OP

Pharmaceutical Schedule - Update News

Nicotine replacement therapy – available on prescription

Nicotine replacement therapy (NRT) will be subsidised on the presentation of either a prescription or a Quit Card from 1 September 2009. This means prescribers will be able to write a prescription for subsidised NRT as an alternative to using Quit Cards. Detailed information is being sent to prescribers and pharmacies explaining

the changes and giving resources where necessary. See page 18 for further information.

Betaloc CR –removal of endorsement and subsidy reduction

The higher subsidy by endorsement criteria that applies to metoprolol succinate (Betaloc CR) long-acting tablets will be removed from 1 September 2009. This means that all patients will be able to receive metoprolol succinate long-acting tablets, fully subsidised irrelevant of the brand, from 1 September 2009. The price and subsidy for all strengths of Betaloc CR long-acting tablets will reduce from 1 September, and further reductions will apply from 1 February and July 2010. See pages 18 and 23 for full details of the changes from 1 September.

6 Pharmaceutical Schedule - Update News

Clopixol tablets – new listing

The antipsychotic Clopixol (zuclopenthixol hydrochloride) 10 mg tablets will be listed fully subsidised without restriction from 1 September 2009.

Insulin syringes and needles – new listings

A new range of insulin pen needles will be subsidised from 1 September 2009. The SC Profi-Fine brand will be available in 29 g x 12.7 mm, 31 g x 5 mm and 31 g x 8 mm. The listing of the 31 g x 6 mm will occur at a later date, yet to be confirmed. The DM Ject brand of insulin syringes, disposable with attached needle, will be listed fully subsidised from 1 September 2009. This brand will be available in the same range of presentations as currently subsidised in the Pharmaceutical Schedule.

Cyclosporin A – removal of Special Authority

The Special Authority applying to cyclosporin A will be removed from 1 September 2009. This means it will be fully subsidised without the need for a Special Authority approval.

Azithromycin Special Authority amendment

Special Authority criteria were added to azithromycin tablets from 1 July 2009 allowing cystic fibrosis patients to access more than 2 tablets of subsidised azithromycin per prescription. From 1 September 2009 the rule allowing Special Authority access will be further amended to waive the requirement for the script to be endorsed. Please note that the use of azithromycin under this Special Authority criteria remains an unapproved indication.

Pharmaceutical Schedule - Update News

Pilocarpine oral liquid standard formulae

With the discontinuation of Pilopt eye drops, the Standard Formulae in Section C (Extemporaneously Compounded Products & Galenicals) of the Pharmaceutical Schedule for pilocarpine oral liquid requires amendment. From 1 September 2009 the strength of pilocarpine eye drops used in the formulae will change from 6% to 4%.

Bromocriptine mesylate new listing and brand change

From 1 September 2009 ApoBromocriptine 5 mg capsules will be fully subsidised on the Pharmaceutical Schedule. These will replace AlphaBromocriptine 10 mg tablets which are being discontinued by Apotex. Apo-Bromocriptine is not a registered medicine, so it must be supplied under Section 29 of the Medicines Act 1981. The listing in the Schedule will indicate the medicine’s Section 29 status and is intended to ensure continuity of subsidised supply. Apo-Bromocriptine 5 mg capsules are currently being assessed by Medsafe.

Tri-phasic oral contraceptives

PHARMAC has received notice that both suppliers (Wyeth and Bayer) of subsidised tri-phasic oral contraceptives intend to discontinue supply within the next 12 months. Tri-phasic oral contraceptives will be delisted 6 months after the final notification from suppliers of stock depletion. The Hormone and Contraceptive Subcommittee of PTAC considered that there was no clinical need for a tri-phasic oral contraceptive to be subsidised and that Brevinor 1 would be an appropriate alternative.

8 Pharmaceutical Schedule - Update News

Panteston capsule brand change

Schering-Plough has notified PHARMAC that its testosterone undecanoate 40 mg capsule, Panteston, has been discontinued worldwide. Schering-Plough has sourced another brand of testosterone undecanoate 40 mg, Andriol Testocap, which will be listed at the same subsidy and price per capsule from 1 September 2009. Unlike Panteston, Andriol Testocap capsules do not require storage in the fridge.

Kenacort-A injection

Kenacort-A (triamcinolone acetonide) injection 10 mg per ml, 1 ml was recorded in the August 2009 Pharmaceutical Schedule as being delisted 1 September 2009. This was an error. Only the 10 mg per ml, 5 ml injection is being delisted from this date. However the 1 ml presentation will be delisted later in 2010 at the request of the supplier.

Anastrozole-DP restriction removal

From 1 September 2009 the ‘subsidy by endorsement’ restriction that currently applies to the prescribing and dispensing of Douglas Pharmaceuticals Limited’s brand of anastrozole (DP-Anastrozole) will be removed. PHARMAC considers that the endorsement created an unnecessary administrative burden on prescribers and removing it should increase the use of DP-Anastrozole in patients with advanced breast cancer. This would result in savings to the community pharmaceuticals budget - savings which may be used to fund other medicines. As with all medicines, prescribers should refer to the medicine Datasheet for information regarding the Medsafe approved indications for DPAnastrozole.

tender News

Sole Subsidised Supply changes – effective 1 October 2009

Chemical Name Azithromycin Chloramphenicol Cyclizine hydrochloride Cyproterone acetate Cyproterone acetate Ethinyloestradoil Felodipine Felodipine Lisinopril Lisinopril Lisinopril Mesalazine Methotrexate Methotrexate Methylprednisolone Methylprednisolone Norethisterone Prednisolone sodium phosphate Roxithromycin Roxithromycin Salbutamol Salbutamol Salbutamol with ipratropium bromide Selegiline hydrochloride Sotalol Sotalol Terazosin hydrochloride Terazosin hydrochloride Timolol maleate Presentation; Pack size Tab 500 mg; 2 tab OP Eye oint 1%; 4 g OP Tab 50 mg; 10 tab Tab 50 mg; 50 tab Tab 100 mg; 50 tab Tab 10 µg; 100 tab Tab long-acting 5 mg; 90 tab Tab long-acting 10 mg; 90 tab Tab 5 mg; 30 tab Tab 10 mg; 30 tab Tab 20 mg; 30 tab Enema 1 g per 100 ml; 7 enema Tab 2.5 mg; 30 tab Tab 10 mg; 50 tab Tab 4 mg; 100 tab Tab 100 mg; 20 tab Tab 350 µg; 84 tab Oral liq 5 mg per ml; 30 ml OP Tab 150 mg; 50 tab Tab 300 mg; 50 tab Nebuliser soln, 1 mg per ml, 2.5 ml; 20 neb Nebuliser soln, 2 mg per ml, 2.5 ml; 20 neb Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml; 20 neb Tab 5 mg; 100 tab Tab 80 mg; 500 tab Tab 160 mg; 100 tab Tab 2 mg; 500 tab Tab 5 mg; 500 tab Tab 10 mg; 100 tab Sole Subsidised Supply brand (and supplier) Arrow-Azithromycin (Arrow) Chlorsig (Sigma) Nausicalm (AFT) Siterone (Rex) Siterone (Rex) NZ Medical and Scientific (NZ Medical and Scientific) Felo 5 ER (Mylan) Felo 10 ER (Mylan) Arrow-Lisinopril (Arrow) Arrow-Lisinopril (Arrow) Arrow-Lisinopril (Arrow) Pentasa (Pharmaco) Methoblastin (Pfizer) Methoblastin (Pfizer) Medrol (Pfizer) Medrol (Pfizer) Noriday 28 (Pfizer) Redipred (Aspen) Arrow-Roxithromycin (Arrow) Arrow-Roxithromycin (Arrow) Asthalin (Rex) Asthalin (Rex) Duolin (Rex) Apo-Selegiline (Apotex) Mylan (Mylan) Mylan (Mylan) Apo-Terazosin (Apotex) Apo-Terazosin (Apotex) Apo-Timol (Apotex)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes to the Pharmaceutical Schedule. It may also assist pharmacists, distributors and wholesalers to manage stock levels. Possible decisions for implementation 1 October 2009 • Alendronate sodium 70 mg with cholecalciferol 5600 iu tab (Fosamax Plus) new listing with existing Special Authority criteria • Alendronate for Osteoporosis – amend Special Authority criteria • Aprepitant (Emend) tri-pack (2 x 80 mg cap and 1 x 125 mg cap) – new listing with Special Authority criteria • Blood glucose diagnostic test meter (On Call Advanced) meter – new listing with existing endorsement criteria • Blood glucose diagnostic test strip (On Call Advanced) blood glucose test strips – new listing with existing endorsement criteria • Blood glucose diagnostic test strip (CareSens II) blood glucose test strips and lancets – new listing with existing endorsement criteria • Blood glucose diagnostic test meter (CareSens II and CareSens POP) meter – new listing with existing endorsement criteria • Blood glucose diagnostic test strip (Accu-Chek Performa) blood glucose test strips – subsidy decrease • Clarithromycin (Klamycin) tab 500 mg – new listing with endorsement criteria for helicobacter pylori eradication • Clarithromycin tab 250 mg – amended Special Authority criteria • Gemcitabine – amended Special Authority criteria • Leuprorelin (Eligard) inj 7.5 mg, 22.5 mg, 30 mg and 45 mg – subsidy decrease • Levodopa with carbidopa tab long-acting 200 mg with carbidopa 50 mg (Sinemet CR) – removal of Retail pharmacy-Specialist • Pioglitazone (Actos) tab 15 mg, 30 mg and 45 mg – subsidy decrease • Raltegravir potassium (Isentress) tab 400 mg – new listing with Special Authority criteria • Risperidone (Risperon) oral liq 1 mg per ml – new listing

Sole Subsidised Supply Products – cumulative to September 2009

Generic Name

Acarbose Acetazolamide Allopurinol Alprazolam Amantadine hydrochloride Amlodipine Amoxycillin

Presentation

Tab 50 mg & 100 mg Tab 250 mg Tab 100 mg & 300 mg Tab 250 µg, 500 µg & 1 mg Cap 100 mg Tab 5 mg & 10 mg Drops 125 mg per 1.25 ml Inj 250 mg, 500 mg & 1 g Cap 250 mg & 500 mg

Brand Name Expiry Date*

Glucobay Diamox Apo-Allopurinol Arrow-Alprazolam Symmetrel Apo-Amlodipine Ospamox Paediatric Drops Ibiamox Apo-Amoxi Synermox AFT Ethics Aspirin Ethics Aspirin EC Atropt Sandoz Fibalip Bicalox Lax-Tabs AFT Marcain Isobaric Marcain Heavy Miacalcic Calsource Calcium Folinate Ebewe Apo-Captopril Ranbaxy-Cefaclor Ranbaxy-Cefaclor Hospira Zinacef PSM Zetop Cetirizine-AFT Orion Batrafen Rex Medical 2012 2011 2011 2010 2011 2011 2011 2010 2011 2011 2010 2011 2011 2011 2011 2010 2011 2010 2011 2011 2011 2010 2010 2011 2011 2010 2011 2011 2012 2011

Amoxycillin clavulanate Aqueous cream Aspirin Atropine sulphate Benzylpenicillin sodium (Penicillin G) Bezafibrate Bicalutamide Bisacodyl Brimonidine tartrate Bupivicaine hydrochloride Calcitonin Calcium Calcium folinate Captopril Cefaclor monohydrate Cefazolin sodium Cefuroxime sodium Cetomacrogol Cetirizine hydrochloride Chlorhexidine gluconate Ciclopiroxolamine Ciprofloxacin

Tab amoxycillin 500 mg with potassium clavulanate 125 mg Crm 500 g Tab dispersible 300 mg Tab 100 mg Eye drops 1% Inj 1 mega u Tab 200 mg Tab 50 mg Tab 5 mg Eye drops 0.2% Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Inj 100 iu per ml, 1 ml Tab eff 1 g Inj 50 mg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Inj 500 mg & 1 g Inj 750 mg & 1.5 g Crm BP Tab 10 mg Oral liq 1 mg per ml Soln 4% Nail soln 8% Tab 250 mg, 500 mg & 750 mg

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated unless otherwise stated. Please note that Sole Subsidised Supply may have been awarded for a wider scope than just those presentation(s) listed in the above table.

Sole Subsidised Supply Products – cumulative to September 2009

Generic Name

Citalopram Clarithromycin Clonazepam Clotrimazole

Presentation

Tab 20 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Tab 500 µg & 2 mg Vaginal crm 2% with applicators(s) Crm 1% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg Powder for soln for oral use Tab 50 mg Inj 500 mg Nasal spray 10 mcg per dose Tab 5 mg Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Arrow-Citalopram Klamycin Klacid Paxam Clomazol Clomazol Clomazol PSM Colgout Colestid Colistin-Link Enerlyte Cycloblastin Mayne Desmopressin-PH&T PSM Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Voltaren Ophtha Voltaren Voltaren Dilzem Cardizem CD Pytazen SR Apo-Doxazosin AFT Clexane Comtan E-Mycin E-Mycin E-Mycin Brevinor 21 Brevinor 1/21 Brevinor 1/28 2010 2010 2011 2010

Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate Compound electrolytes Cyclophosphamide Desferrioxamine mesylate Desmopressin Dexamphetamine sulphate Dextrose Dextrose with electrolytes

2010 2010 2010 2010 2010 2010 2010 2011 2010 2011 2010

Diclofenac sodium

Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg, 25 mg, 50 mg & 100 mg Tab 30 mg & 60 mg Cap long-acting 120 mg, 180 mg & 240 mg Tab long-acting 150 mg Tab 2 mg & 4 mg Oint BP Inj 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg & 150 mg Tab 200 mg Tab 400 mg Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab

2011

Diltiazem hydrochloride

2011

Dipyridamole Doxazosin mesylate Emulsifying ointment Enoxaparin sodium (low molecular weight heparin) Entacapone Erythromycin ethyl succinate

2011 2010 2011 2012 2012 2012 2011 2010

Ethinyloestradiol with norethisterone

Sole Subsidised Supply Products – cumulative to September 2009

Generic Name

Ferrous sulphate Finasteride Flucloxacillin Fluconazole Fludarabine phosphate Fluocortolone caproate with fluocortolone pivalate and cinchocaine

Presentation

Oral liq 150 mg per 5 ml Tab 5 mg Inj 250 mg, 500 mg & 1 g Cap 50 mg, 150 mg & 200 mg Inj 50 mg Tab 10 mg Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Cap 20 mg Tab disp 20 mg, scored Tab 40 mg Crm 2% Oint 2% Cap 100 mg, 300 mg & 400 mg Tab 80 mg Tab 5 mg Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg & 10 mg

Brand Name Expiry Date*

Ferodan Fintral Flucloxin Pacific Fludara Fludara Oral Ultraproct Ultraproct 2010 2011 2011 2011 2011 2010

Fluoxetine hydrochloride Furosemide Fusidic acid Gabapentin Gliclazide Glipizide Glyceryl trinitrate

Fluox Fluox Diurin 40 Foban Foban Nupentin Apo-Gliclazide Minidiab Lycinate Nitrolingual pumpspray Nitroderm TTS Serenace Serenace PSM Locoid DP Lotn HC Plaquenil Methopt Buscopan Gastrosoothe Ethics Ibuprofen Fenpaed Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Ferrum H Sporanox

2010 2012 2010 31/7/12 2011 2011 2011

Haloperidol Hydrocortisone Hydrcortisone butyrate Hydrocortisone with wool fat and mineral oil Hydroxychloroquine sulphate Hypromellose Hysocine N-butylbromide Ibuprofen Ipratropium bromide

Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Crm 1% Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Tab 200 mg Eye drops 0.5% Inj 20 mg, 1 ml Tab 20 mg Tab 200 mg Oral liq 100 mg per 5 ml Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Inj 50 mg per ml, 2 ml Cap 100 mg

2010 2011 2010 2011 2012 2011 2011 2012 2010 2010

Iron polymaltose Itraconazole

2011 2010

Sole Subsidised Supply Products – cumulative to September 2009

Generic Name

Ketoconazole Lactulose Levobunolol Lignocaine hydrochloride

Presentation

Shampoo 2% Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Sebizole Duphalac Betagan Xylocaine Xylocaine Xylocaine EMLA EMLA Nodia Loraclear Hayfever Relief Lorapaed Derbac M A-Lices Foremount Child’s Silicone Mask De-Worm Colofac Provera Biodone Biodone Forte Biodone Extra Forte Methatabs Methotrexate Ebewe Methotrexate Ebewe Prodopa Depo-Medrol Depo-Medrol with Lidocaine Pfizer Multichem Mayne Mayne Apo-Nadolol ReVia Sonaflam AstraZeneca 2010 2010 2011 2010 2010 2010

Lignocaine with prilocaine

2010

Loperamide hydrochloride Loratadine

Malathion Mask for Spacer Device Mebendazole Mebeverine hydrochloride Medroxyprogesterone acetate Methadone hydrochloride

Liq 0.5% Shampoo 1% Device Tab 100 mg Tab 135 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Tab 5 mg Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 125 mg, 250 mg, 500 mg Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 5 mg per ml, 2 ml Crm 2% Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Tab 40 mg & 80 mg Tab 50 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml

2010 2011 30/9/11 2011 2011 2010 2012 2010 2011 2011 2011 2011 2011 2011 2011 2010 2010 2010 2010

Methotrexate Methyldopa Methylprednisolone acetate Methylprednisolone acetate with lignocaine Metoclopramide hydrochloride Miconazole nitrate Morphine sulphate Nadolol Naltrexone hydrochloride Naproxen sodium Neostigmine

Sole Subsidised Supply Products – cumulative to September 2009

Generic Name

Nicotine

Presentation

Patch 7 mg, 14 mg and 21 mg Lozenge 1 mg and 2 mg Gum 2 mg & 4 mg (Fruit) Gum 2 mg & 4 mg (Mint) Tab 5 mg Tab 10 mg & 25 mg Oral liq 100,000 u per ml, 24 ml OP Cap 500,000 u Tab 500,000 u Cap 10 mg, 20 mg & 40 mg Inj 40 mg

Brand Name Expiry Date*

Habitrol Habitrol Habitrol Habitrol Primolut N Norpress Nilstat Nilstat Nilstat Dr Reddy’s Omeprazole Dr Reddy’s Omeprazole Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Pamisol Pamisol Pamisol Pantocid IV Dr Reddy’s Pantoprazole Pharmacare Paracare Junior Paracare Double Strength Lacri-Lube Loxamine Breath-Alert Permax AFT AFT Cilicaine VK Prefrin Coloxyl Vistil Vistil Forte Apo-Prazo Apo-Prednisone 2010

Norethisterone Nortriptyline hydrochloride Nystatin

2011 2011 2011 2010 2011

Omeprazole

Ondansetron Oxybutynin Oxycodone hydrochloride Pamidronate disodium

Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml & 2 ml Oral liq 5 mg per 5 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Inj 40 mg Tab 20 mg & 40 mg Tab 500 mg Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Eye oint with soft white paraffin Tab 20 mg Low range and Normal range Tab 0.25 mg & 1 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg & 500 mg Eye drops 0.12% Oral drops 10% Eye drops 1.4% Eye drops 3% Tab 1 mg, 2 mg & 5 mg Tab 1 mg, 2.5 mg, 5 mg & 20 mg

2010 2010 2010 2011

Pantoprazole

2010

Paracetamol

2011

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Peak Flow Meter Pergolide Phenoxymethylpenicillin (Penicillin V) Phenylephrine hydrochloride Poloxamer Polyvinyl alcohol Prazosin hydrochloride Prednisone

2010 2010 30/9/11 2011 2010

2010 2011 2011 2010 2011

Sole Subsidised Supply Products – cumulative to September 2009

Generic Name

Procaine penicillin Promethazine Quinapril Quinapril with hydroclorothiazide

Presentation

Inj 1.5 mega u Tab 10 mg & 25 mg Tab 5 mg, 10 mg & 20 mg Tab 10 mg with hydroclorothiazide 12.5 mg Tab 20 mg with hydroclorothiazide 12.5 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 0.25 mg, 1 mg, 2 mg and 5 mg Oral liq 2 mg per 5 ml Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg Grans eff 4 g sachets 230 ml Liq Soln 2.3% Tab 10 mg Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 mcg Inj 1 mg per ml, 1 ml Eye drops 0.25% & 0.5% Crm 0.02% Oint 0.02% Inj 40 mg per ml, 1 ml 0.1% in Dental Paste USP Tab 300 mg Cap 300 mg Inj 50 mg per ml, 10 ml Ointment BP Cap 220 mg Tab 7.5 mg

Brand Name Expiry Date*

Cilicaine Allersoothe Accupril Accuretic 10 Accuretic 20 Peptisoothe Mycobutin Ropin Salapin Arrow-Simva 10 mg Arrow-Simva 20 mg Arrow-Simva 40 mg Arrow-Simva 80 mg Ural Space Chamber Midwest Pinetarsol Normison Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot Apo-Timop Aristocort Aristocort Kenacort-A40 Oracort TMP Actigall Pacific PSM Zincaps Apo-Zopiclone 2010 2010 2010 2010 2011 2011 2011 2011 2011

Ranitidine hydrochloride Rifabutin Ropinirole hydrochloride Salbutamol Simvastatin

Sodium citro-tartrate Spacer Device Syrup (pharmaceutical grade) Tar with triethanolamine lauryl sulphate and fluorescein Temazepam Terbinafine Testosterone cypionate Tetracosactrin Timolol maleate Triamcinolone acetonide

2010 30/9/11 2010 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011 2011

Trimethoprim Ursodeoxycholic acid Vancomycin hydrochloride Zinc and castor oil Zinc sulphate Zopiclone September changes in bold

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 September 2009

32 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ❋ 29 g × 12.7 mm .................................................................... 11.75 ❋ 31 g × 5 mm ......................................................................... 11.75 ❋ 31 g × 8 mm ......................................................................... 11.75 100 100 100 ✔ SC Profi-Fine ✔ SC Profi-Fine ✔ SC Profi-Fine

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE – Maximum of 100 dev per prescription ❋ Syringe 0.3 ml with 29 g × 12.7 mm needle .......................... 13.00 100 ✔ DM Ject ❋ Syringe 0.3 ml with 31 g × 8 mm needle ............................... 13.00 100 ✔ DM Ject ❋ Syringe 0.5 ml with 29 g × 12.7 mm needle .......................... 13.00 100 ✔ DM Ject ❋ Syringe 0.5 ml with 31 g × 8 mm needle ............................... 13.00 100 ✔ DM Ject ❋ Syringe 1 ml with 29 g × 12.7 mm needle ............................. 13.00 100 ✔ DM Ject ❋ Syringe 1 ml with 31 g × 8 mm needle .................................. 13.00 100 ✔ DM Ject CLOPIDOGREL – Special Authority see SA0867 – Retail pharmacy Tab 75 mg .............................................................................. 25.00 ISOTRETINOIN – Special Authority see SA0955 – Retail pharmacy Cap 10 mg .............................................................................. 48.48 Cap 20 mg ............................................................................. 69.70 TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist Cap 40 mg .............................................................................. 60.71 BROMOCRIPTINE MESYLATE ❋ Cap 5 mg ............................................................................... 60.43 ZUCLOPENTHIXOL HYDROCHLORIDE Tab 10 mg .............................................................................. 31.45 28 180 180 60 100 ✔ Arrow-Clopidogrel ✔ Oratane ✔ Oratane ✔ Andriol Testocaps ✔ Apo-Bromocriptine

S29

40 58

76 119

123

100

✔ Clopixol

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 September 2009

31 KETONE BLOOD BETA-KETONE ELECTRODES – Subsidy by endorsement Patient has type 1 diabetes and has had one or more episodes of ketoacidosis (excluding first presentation). Maximum quantity of 2 packs per annum. No further prescriptions will be subsidised. The prescription must be endorsed accordingly. Test strip – Not on a BSO .......................................................... 8.50 10 strip OP ✔ Optium Blood Ketone Test Strips METOPROLOL SUCCINATE Additional subsidy by endorsement for Betaloc CR is available for patients who: 1) were being prescribed metoprolol succinate prior to 1 October 2007; or 2) have experienced a myocardial infarction; or 3) have experienced heart failure and are either intolerant of carvedilol or it is contra-indicated. Pharmacists may annotate prescriptions for patients who were being prescribed metoprolol succinate prior to 1 October 2007 in which case the prescription is deemed to be endorsed. The pharmacist must be able to show a clear documented dispensing history for the patient. The prescription must be endorsed accordingly. ❋ Tab long-acting 23.75 mg – Higher subsidy of up to $6.20 per 30 with Endorsement ............................................................. 3.61 30 ✔ Betaloc CR ❋ Tab long-acting 47.5 mg – Higher subsidy of up to $7.80 per 30 with Endorsement ............................................................. 4.50 30 ✔ Betaloc CR ❋ Tab long-acting 95 mg – Higher subsidy of up to $13.20 per 30 with Endorsement ............................................................. 7.40 30 ✔ Betaloc CR ❋ Tab long-acting 190 mg – Higher subsidy of up to $21.00 per 30 with Endorsement ........................................................... 12.50 30 ✔ Betaloc CR NICOTINE – Only on a Quitcard a) Maximum of 28 patch per dispensing b) Maximum of 56 patch per prescription c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. Patch 7 mg ............................................................................ 10.53 7 OP ✔ Habitrol Patch 14 mg .......................................................................... 11.63 7 OP ✔ Habitrol Patch 21 mg .......................................................................... 12.32 7 OP ✔ Habitrol NICOTINE – Only on a Quitcard a) Maximum of 216 loz per dispensing b) Maximum of 432 loz per prescription c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. Lozenge 1 mg ........................................................................ 11.08 36 OP ✔ Habitrol Lozenge 2 mg ........................................................................ 11.08 36 OP ✔ Habitrol NICOTINE – Only on a Quitcard a) Maximum of 384 piece per dispensing b) Maximum of 768 piece per prescription c) For the avoidance of doubt Nicotine will not be funded Close Control in amounts less than 4 weeks. Gum 2 mg (Fruit) .................................................................... 14.97 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 2 mg (Mint) .................................................................... 14.97 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 4 mg (Fruit) .................................................................... 20.02 96 OP ✔ Habitrol 23.41 ✔ Nicotinell Gum 4 mg (Mint) .................................................................... 20.02 96 OP ✔ Habitrol 23.41 ✔ Nicotinell

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

81 GOSERELIN ACETATE – Special Authority see SA0839 – Hospital pharmacy [HP3] Inj 3.6 mg ............................................................................. 221.60 1 ✔ Zoladex Inj 10.8 mg .......................................................................... 554.70 1 ✔ Zoladex ➽ SA0839 Special Authority for Subsidy Initial application — (Breast cancer) from any medical practitioner. Approvals valid for 1 year where the patient is a premenopausal woman with breast cancer. Initial application — (Prostate cancer) only from an oncologist, urologist or endocrinologist. Approvals valid for 1 year for applications meeting the following criteria: Either: 1 Advanced prostatic cancer; or 2 Neoadjuvant or adjuvant treatment of locally advanced prostatic cancer. Note: Not to be prescribed with an anti-androgen except for a period of three weeks, if necessary, when GnRH analogue therapy is intiated. Initial application — (Endometriosis) only from a gynaecologist. Approvals valid for 3 months for applications meeting the following criteria: Both: 1 Endometriosis; and 2 Either: 2.1 6 months treatment with medroxyprogesterone acetate, danazol or dimetriose has proven ineffective; or 2.2 The patient has failed to tolerate the treatment with medroxyprogesterone acetate, danazol or dimetriose for 6 months. Note: The maximum treatment period for a GnRH analogue is: • 3 months to assess whether surgery is appropriate • 3 months for infertile patients after surgery • 6 months for patients with symptoms of endometriosis After the first 3 months patients should be assessed to determine whether there has been a satisfactory response to the first 3 months treatment. Initial application — (Precocious puberty) only from a paediatrician or endocrinologist. Approvals valid for 1 year where the patient is affected by gonadotropin dependent precocious puberty. Renewal — (Breast or prostate cancer) from any medical practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application. Renewal — (Endometriosis) from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Either: 1 Both: 1.1 There has been a satisfactory response to the first 3 months treatment; and 1.2 Surgery is inappropriate; or 2 The first three months of therapy did not follow surgery for infertility. Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application. Renewal — (Precocious puberty) only from a paediatrician or endocrinologist. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment. Note: If a patient had an approval for any GnRH analogue prior to 1 July 2006 the applicant is required to submit a fresh initial application, not a renewal application.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

83 AZITHROMYCIN – Subsidy by endorsement a) Maximum of 2 tab per prescription; can be waived by Special Authority see SA0964 b) Up to 4 tab available on a PSO c) Subsidised only if prescribed for patients with uncomplicated urethritis or cervicitis proven or presumed to be due to chlamydia trachomatis and their sexual contacts and prescription or PSO is endorsed accordingly; can be waived by Special Authority see SA0964. Tab 500 mg ............................................................................. 5.95 2 OP ✔ Arrow-Azithromycin ENTECAVIR – Special Authority see SA0977 – Retail pharmacy Tab 0.5 mg ........................................................................... 400.00 30 ✔ Baraclude ➽ SA0977 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and 3 Entecavir dose 0.5 mg/day; and 4 Either: 4.1 ALT greater than upper limit of normal; or 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and 5 Either: 5.1 HBeAg positive; or 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and 6 No continuing alcohol abuse or intravenous drug use; and 7 Not co-infected with HCV, HIV or HDV; and 8 Neither ALT nor AST greater than 10 times upper limit of normal; and 9 No history of hypersensitivity to entecavir; and 10 No previous documented lamivudine resistance (either clinical or genotypic). Notes: • Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4). • Entecavir should be taken on an empty stomach to improve absorption. TRANYLCYPROMINE SULPHATE Tab 10 mg ............................................................................. 22.94 Note – removal of Section 29 annotation 50 ✔ Parnate S29 S29

112

143

ANASTROZOLE-DP – Subsidy by endorsement Subsidised only for patients with hormone receptor positive advanced breast cancer and the prescription is endorsed accordingly. Tab 1 mg ............................................................................... 29.50 30 ✔ DP-Anastrozole CYCLOSPORIN A – Special Authority see SA0470 – Hospital pharmacy [HP3] Cap 25 mg ............................................................................. 85.00 50 Cap 50 mg ........................................................................... 169.34 50 Cap 100 mg ......................................................................... 338.69 50 Oral liq 100 mg per ml .......................................................... 377.38 50 ml OP ➽ SA0470 Special Authority for Subsidy ✔ Neoral ✔ Neoral ✔ Neoral ✔ Neoral continued...

147

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

continued... Initial application — (Organ transplant) only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient. Initial application — (Bone marrow transplant or Graft v host disease) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Bone marrow transplant; or 2 Graft v host disease. Initial application — (Psoriasis) only from a dermatologist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Psoriasis; and 2 Applicant must state which systemic and topical therapies have failed. Initial application — (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Severe atopic dermatitis; and 2 Not responsive to topical therapy, oral antihistamines and other commonly used orthodox therapies. Initial application — (Nephrotic Syndrome) only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Nephrotic Syndrome; and 2 Corticosteroid dependent patients who have failed on cytotoxic therapy. Initial application — (Endogenous uveitis) only from a relevant specialist. Approvals valid for 2 years where the patient suffers from endogenous uveitis. Initial application — (Severe rheumatoid arthritis) only from a rheumatologist. Approvals valid for 2 years for applications meeting the following criteria: All of the following: 1 Severe rheumatoid arthritis; and 2 The patient must be either unresponsive to or unable to tolerate, both sulphasalazine and methotrexate; and 3 Patients must have 2 serum creatinine test results within the normal range within the three months prior to initiation of therapy. Renewal — (Severe atopic dermatitis) only from a dermatologist. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. Renewal — (Indications other than severe atopic dermatitis) only from a dermatologist, rheumatologist or relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Guidelines for use of cyclosporin A in rheumatoid arthritis Monitoring: All patients require frequent monitoring for creatinine levels and blood pressure: • fortnightly, in the first three months of therapy and then monthly, if results are stable; • if dose is increased or there is a rise in serum creatinine or blood pressure, then more frequent monitoring is required. Contraindications: Cyclosporin A is contraindicated in patients with the following conditions: • current or past malignancy; • uncontrolled hypertension; • renal dysfunction (abnormal serum creatinine for age and sex); • immunodeficiency and neutropenia; • abnormally low white blood cell count or platelet count; or • liver function tests more than twice the upper limit of normal. Caution in use: • age above 65 years; continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2009 (continued)

continued... • controlled hypertension; • use of anti-epileptic medications; • use of ketoconazole, fluconazole, trimethoprim, erythromycin, verapamil, and diltiazem; • concurrent or previous use of alkylating agents such as cyclophosphamide; • use of any experimental drug within the past three months; • premalignant conditions such as leukoplakia, monoclonal paraproteinaemia, myelodysplastic syndrome and dysplastic naevi; • active infection may necessitate temporary discontinuation; • pregnancy and lactation. Therapy should be discontinued if there has been no improvement after 6 months with the patient on the maximum tolerated dose. For further information please consult the data sheet. PILOCARPINE ORAL LIQUID Pilocarpine 4% 6% eye drops qs Preservative qs Water to 500 ml (Preservative should be used if quantity supplied is for more than 5 days.)

166

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 September 2009

32 40 INSULIN PEN NEEDLES – Maximum of 100 dev per prescription ( subsidy) ❋ 31 g × 5 mm ......................................................................... 11.75 100 ✔ B-D Micro-Fine ✔ Apo-Clopidogrel Plavix ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR ✔ Betaloc CR

CLOPIDOGREL – Special Authority see SA0867 – Retail pharmacy ( subsidy) Tab 75 mg ............................................................................. 25.00 28 (73.38) METOPROLOL SUCCINATE ( subsidy) ❋ Tab long-acting 23.75 mg ......................................................... 3.61 ❋ Tab long-acting 47.5 mg ........................................................... 4.50 ❋ Tab long-acting 95 mg .............................................................. 7.40 ❋ Tab long-acting 190 mg .......................................................... 12.50 POVIDONE IODINE ( subsidy) Skin preparation, povidone iodine 10% with 30% alcohol ....................................................................... 10.00 DANAZOL – Retail pharmacy-Specialist ( subsidy) Cap 100 mg ........................................................................... 20.50 68.33 Cap 200 mg ........................................................................... 29.35 BETAHISTINE DIHYDROCHLORIDE ( subsidy) ❋ Tab 16 mg ............................................................................... 9.26 30 30 30 30

500 ml 30 100 30 84

✔ Betadine Skin Prep ✔ D-Zol ✔ Azol ✔ D-Zol ✔ Vergo 16 ✔ Baxter ✔ Flutamin

117 141 143 155

VINORELBINE – PCT only – Specialist – Special Authority see SA0901 ( subsidy) Inj 1 mg for ECP ....................................................................... 2.71 1 mg FLUTAMIDE – Hospital pharmacy [HP3]-Specialist ( subsidy) Tab 250 mg ........................................................................... 48.30 100

BUDESONIDE ( price) Metered aqueous nasal spray, 50 µg per dose .......................... 2.35 200 dose OP (4.00) Metered aqueous nasal spray, 100 µg per dose ........................ 2.61 200 dose OP (4.81) FLUOROMETHOLONE ( subsidy) ❋ Eye drops 0.1% ........................................................................ 4.05 (4.30) 5 ml OP

Butacort Aqueous Butacort Aqueous

158

Flucon

175

ORAL FEED 1KCAL/ML – Special Authority see SA0589 – Hospital pharmacy [HP3] ( subsidy) Liquid ........................................................................................ 1.90 200 ml OP ✔ Fortimel

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Sole Subsidised Supply

Effective 1 September 2009

For the list of new Sole Subsidised Supply products effective 1 September 2009 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 11-16.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 September 2009

32 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and the prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly. Blood glucose test strips ........................................................ 22.00 50 test OP ✔ Optium 10 second test 11.00 25 test OP ✔ Optium 10 second test GLYCEROL ❋ Suppos 2.55 g – Only on a prescription .................................... 3.12 LABETALOL ❋ Inj 5 mg per ml, 5 ml .............................................................. 14.77 (22.15) 12 ✔ Fleet Glycerin Suppositories

Trandate S29

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Only on a prescription............. 3.00 15 g OP ETHINYLOESTRADIOL WITH GESTODENE ❋ Tab 30 µg with gestodene 75 µg and 7 inert tab ....................... 6.62 84 (14.49) a) Higher subsidy of $14.49 per 84 with Special Authority see SA0500 above b) Up to 84 tab available on a PSO

✔ Kenacomb

Minulet 28

ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab ethinyloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinyloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab ............................................................... 6.62 84 (14.49) Triphasil 28 a) Higher subsidy of up to $14.49 per 84 with Special Authority see SA0500 on the preceding page b) Up to 84 tab available on a PSO TRIAMCINOLONE ACETONIDE Inj 10 mg per ml, 5 ml ............................................................ 10.31 DICLOXACILLIN Cap 250 mg ............................................................................. 2.47 (4.35) Cap 500 mg ............................................................................. 3.83 (8.65) 1 24 Diclocil 24 Diclocil ✔ Kenacort-A

76 85

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items – effective 1 September 2009 (continued)

120 ROPINIROLE HYDROCHLORIDE ▲ Tab 0.25 mg .......................................................................... 19.75 (31.50) ▲ Tab 0.25 mg × 42, 0.5 mg × 42 and 1 mg × 21 .................. 21.92 (35.70) ▲ Tab 0.5 mg × 42, 1 mg × 42 and 2 mg × 63 ....................... 73.60 (122.11) ▲ Tab 1 mg ............................................................................... 40.32 (67.20) ▲ Tab 2 mg ............................................................................... 60.72 (101.21) ▲ Tab 5 mg ............................................................................... 90.00 (150.00) 174 210 Requip 105 Requip Starter Pack 147 Requip Follow-on Pack 84 Requip 84 Requip 84 Requip

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 – Hospital pharmacy [HP3] Liquid ........................................................................................ 7.50 1,000 ml OP ✔ Resource Diabetic TF RTH

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 December 2009

158 FLUOROMETHOLONE ❋ Eye drops 0.1% ........................................................................ 4.05 (4.30) 5 ml OP Flucon

Effective 1 March 2010

97 PEGYLATED INTERFERON ALPHA-2B WITH RIBAVIRIN – Special Authority see SA0953 – Hospital pharmacy [HP3] See prescribing guideline Inj 50 µg × 4 with ribavirin cap 200 mg × 112 ................. 1,080.40 1 OP ✔ Pegatron Combination Therapy Inj 50 µg × 4 with ribavirin cap 200 mg × 84 ...................... 976.80 1 OP ✔ Pegatron Combination Therapy Inj 80 µg × 4 with ribavirin cap 200 mg × 140 ................. 1,583.60 1 OP ✔ Pegatron Combination Therapy Inj 80 µg × 4 with ribavirin cap 200 mg × 168 ................. 1,687.20 1 OP ✔ Pegatron Combination Therapy Inj 80 µg × 4 with ribavirin cap 200 mg × 84 ................... 1,376.40 1 OP ✔ Pegatron Combination Therapy Inj 100 µg × 4 with ribavirin cap 200 mg × 112 ............... 1,746.40 1 OP ✔ Pegatron Combination Therapy Inj 100 µg × 4 with ribavirin cap 200 mg × 84 ................. 1,642.80 1 OP ✔ Pegatron Combination Therapy Inj 120 µg × 4 with ribavirin cap 200 mg × 140 ............... 2,116.40 1 OP ✔ Pegatron Combination Therapy Inj 120 µg × 4 with ribavirin cap 200 mg × 84 ................. 1,909.20 1 OP ✔ Pegatron Combination Therapy Inj 150 µg × 4 with ribavirin cap 200 mg × 140 ............... 2,516.00 1 OP ✔ Pegatron Combination Therapy Inj 150 µg × 4 with ribavirin cap 200 mg × 168 ............... 2,619.60 1 OP ✔ Pegatron Combination Therapy Inj 150 µg × 4 with ribavirin cap 200 mg × 84 ................. 2,308.80 1 OP ✔ Pegatron Combination Therapy TRIMIPRAMINE MALEATE Cap 25 mg ............................................................................... 6.20 100 ✔ Tripress

112

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted – effective 1 March 2010 (continued)

115 119 125 LAMOTRIGINE ▲ Tab dispersible 200 mg ........................................................ 101.80 BROMOCRIPTINE MESYLATE ❋ Tab 10 mg ........................................................................... 120.86 DIAZEPAM Tab 5 mg – Month Restriction.................................................... 5.00 ‡ Safety cap for extemporaneously compounded oral liquid preparations. PACLITAXEL – PCT only – Specialist Inj 30 mg ............................................................................... 37.95 Note – Paclitaxel Ebewe inj 30 mg, 5 inj pack remains listed. PILOCARPINE ❋ Eye drops 1% ........................................................................... 3.24 56 100 250 ✔ Mogine ✔ Alpha-Bromocriptine ✔ Pro-Pam

140

✔ Paclitaxel Ebewe

160 183

15 ml OP

✔ Pilopt

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Corn and Spinach Rigatini.......................................................... 2.00 250 g OP (2.92) Garlic and Parsley Shells ........................................................... 2.00 250 g OP (2.92) Rice and Corn Garden Herb Pasta .............................................. 2.00 250 g OP (2.92)

Orgran Orgran Orgran

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 September 2009

ACICLOVIR Inj 250 mg 25 mg per ml, 10 ml .....Pfizer 25.50 5 1% Nov-09 Acihexal Hospira Lovir m-Aciclovir Zovirax

Note – Mayne brand of aciclovir inj 250 mg to be delisted 1 November 2009. BACLOFEN Inj 10 mg........................................Lioresal Intrathecal BETAHISTINE DIHYDROCHLORIDE ( price) Tab 16 mg......................................Vergo 16 BLOOD GLUCOSE DIAGNOSTIC TEST METER Meter .............................................Optium Xceed 190.08 1 1% Nov-09 (B)

9.26 9.00

84 1

BUDESONIDE ( price) Metered aqueous nasal spray, 50 µg per dose ..........................Butacort Aqueous 4.00 Metered aqueous nasal spray, 100 µg per dose ........................Butacort Aqueous 4.81 CASPOFUNGIN Inj 50 mg........................................Cancidas Inj 70 mg........................................Cancidas CHLORHEXIDINE Crm 1 % obstetric ...........................healthE 667.50 862.50 1.36

200 doses 200 doses 1 1 50 g 1% 1% 1% Nov-09 Nov-09 Nov-09 (B) (B) Hibitane Orion PSM

Note – Orion brand of chlorhexidine crm 1% obstetric to be delisted 1 November 2009. CLONAZEPAM ( price) Inj 1 mg per ml, 1 ml ......................Rivotril CLOPIDOGREL Tab 75 mg ( price)........................Apo-Clopidogrel Tab 75 mg (new listing) ..................Arrow -Clopidogrel 19.00 25.00 25.00 5 28 28

DANAZOL ( price) Cap 100 mg ...................................D-Zol 20.50 30 Azol 68.33 100 Cap 200 mg ...................................D-Zol 29.35 30 Note – D-Zol brand of danazol cap 100 mg 30 pack size to be delisted 1 October 2009

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 September 2009 (continued)

DIAZEPAM Tab 5 mg........................................Pro-Pam 5.00 Note – Pro-Pam tab 5 mg to be delisted 1 November 2009. FLUTAMIDE ( price) Tab 250 mg ...................................Flutamin HYDROXYETHYL STARCH 130/0.4 Inj 6 %............................................Voluven INSULIN PEN NEEDLES 29 g x 12.7 mm..............................SC Profi-Fine 31 g x 5 mm...................................SC Profi-Fine 31 g x 8 mm...................................SC Profi-Fine 48.30 198.00 11.75 11.75 11.75 250

100 20 100 100 100 1% Nov-09 Venofundin 6%

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE Syringe 0.3 ml with 29 g x 12.7 mm needle ......................DM Ject 13.00 Syringe 0.3 ml with 31 g x 8 mm needle ...........................DM Ject 13.00 Syringe 0.5 ml with 29 g x 12.7 mm needle ......................DM Ject 13.00 Syringe 0.5 ml with 31 g x 8 mm needle ...........................DM Ject 13.00 Syringe 1 ml with 29 g x 12.7 mm needle ......................DM Ject 13.00 Syringe 1 ml with 31 g x 8 mm needle ...........................DM Ject 13.00 ISOTRETINOIN Cap 10 mg .....................................Oratane Cap 20 mg .....................................Oratane 48.48 69.70

100 100 100 100 100 100 180 180 1% 1% Nov-09 Nov-09 Isotane 10 Roaccutane Isotane 20 Roaccutane

Note – Isotane 10 and Isotane 20 to be delisted 1 November 2009. LAMOTRIGINE Tab dispersible 200 mg ..................Mogine 101.80 56 Note – Mogine tab dispersible 200 mg to be delisted 1 November 2009 LIGNOCAINE Gel 2% ...........................................Xylocaine Jelly 6.00 30 ml Note – Orion brand of lignocaine gel 2% to be delisted 1 November 2009. METOPROLOL SUCCINATE Tab long-acting 23.75 mg...............Betaloc CR Tab long-acting 47.5 mg.................Betaloc CR Tab long-acting 95 mg....................Betaloc CR Tab long-acting 190 mg..................Betaloc CR 3.61 4.50 7.40 12.50 30 30 30 30 1% Nov-09 Orion

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 September 2009 (continued)

ONDANSETRON HYDROCHLORIDE ( price) Inj 2 mg per ml, 2 ml ......................Zofran Hospira Ondansetron Sandoz Onsetron Inj 2 mg per ml, 4 ml ......................Zofran 23.20 5 1% Nov-09 Hospira Ondansetron Sandoz Onsetron Note – The Mayne brand of ondansetron inj 2 mg per ml, 2 ml and 4 ml to be delisted 1 November 2009. Anzatax Taxol Note – Paclitaxel Ebewe inj 30 mg, 1 inj pack, to be delisted 1 November 2009. Please note that the 5 inj pack remains listed. 1 1% Oct-08 14.40 5 1% Nov-09

PACLITAXEL Inj 30 mg........................................Paclitaxel Ebewe 37.95

POVIDONE IODINE Alcohol skin preparation 10% with 30 % alcohol ( price).........Betadine Skin Prep Antiseptic soln 10% ( price) ..........Betadine Oint 10 % ( price) .........................Betadine ZUCLOPENTHIXOL HYDROCHLORIDE Tab 10 mg......................................Clopixol

10.00 6.20 3.27 31.45

500 ml 500 ml 25 g 100

Effective 1 August 2009

ATENOLOL ( price) Tab 50 mg......................................Pacific Atenolol 6.18 500 1% Oct-09 Anselol Apo-Atenolol Atehexal Global Atenolol Anselol Apo-Atenolol Atehexal Global Atenolol

Tab 100 mg ...................................Pacific Atenolol

10.73

500

Oct-09

CLOZAPINE ( price) Oral liq 50 mg per ml ......................Clopine Tab 25 mg......................................Clopine Clopine Tab 50 mg......................................Clopine Clopine Tab 100 mg....................................Clopine Clopine Tab 200 mg....................................Clopine Clopine

17.33 6.69 13.37 8.67 17.33 17.33 34.65 34.65 69.30

100 ml 50 100 50 100 50 100 50 100

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 August 2009 (continued)

DASATINIB Tab 20 mg......................................Sprycel Tab 50 mg......................................Sprycel Tab 70 mg......................................Sprycel DESFLURANE Liq 240 ml bottle ............................Suprane ENOXAPARIN SODIUM Inj 20 mg .......................................Clexane Inj 40 mg .......................................Clexane Inj 60 mg .......................................Clexane Inj 80 mg .......................................Clexane Inj 100 mg .....................................Clexane Inj 120 mg .....................................Clexane Inj 150 mg .....................................Clexane ENTECAVIR Tab 0.5 mg.....................................Baraclude EPIRUBICIN Inj 2 mg per ml, 5 ml ( price) ........Epirubicin Ebewe Inj 2 mg per ml, 25 ml ( price) ......Epirubicin Ebewe Inj 2 mg per ml, 50 ml ( price) ......Epirubicin Ebewe Inj 2 mg per ml, 100 ml ( price) ....Epirubicin Ebewe FENTANYL CITRATE (amended chemical name) Inj 50 µg per ml, 2 ml .....................Hospira Inj 50 µg per ml, 10 ml ...................Hospira 3,774.06 6,214.20 7,692.58 1,230.00 39.20 52.30 78.85 105.12 135.20 168.00 192.00 400.00 25.00 87.50 155.00 310.00 60 60 60 6 10 10 10 10 10 10 10 30 1 1 1 1 1% 1% 1% 1% Oct-09 Oct-09 Oct-09 Oct-09 Hospira Pharmorubicin Hospira Pharmorubicin Hospira Pharmorubicin Hospira Pharmorubicin 1% 1% 1% 1% 1% 1% 1% 1% Nov-09 Aug-09 Aug-09 Aug-09 Aug-09 Aug-09 Aug-09 Aug-09 (B) (B) (B) (B) (B) (B) (B) (B)

6.10 15.65

5 5

Nupentin 5% Aug-09 Neurontin GABAPENTIN Cap 100 mg ( price) .....................Nupentin 7.16 100 Cap 300 mg ( price) .....................Nupentin 11.50 100 Cap 400 mg ( price) .....................Nupentin 14.75 100 Note – The DV limit of 5% applies to the gabapentin chemical rather than each individual line item. Note – Neurontin cap 100 mg, 300 mg and 400 mg, and tab 600 mg delisted 1 August 2009. ISOFLURANE Liq 250 ml bottle ............................Aerrane 540.00 6 1% Nov-09 Forthane Rhodia

Note – Forthane liq 250 ml bottle to be delisted 1 November 2009

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II - effective 1 August 2009 (continued)

LEUPRORELIN Inj 3.75 mg prefilled syringe............Lucrin Depot PDS Inj 11.25 mg prefilled syringe ..........Lucrin Depot PDS Inj 30 mg prefilled syringe...............Lucrin Depot PDS NEVIRAPINE Oral suspension 10 mg per ml ........Viramune Suspension Tab 200 mg....................................Viramune OIL IN WATER EMULSION Crm................................................healthE Fatty Cream PARAFFIN Yellow soft .....................................API SAQUINAVIR Tab 500 mg....................................Invirase Note – Invirase to be delisted 1 February 2010 221.60 591.68 1,109.40 1 1 1

134.55 319.80 2.80

240 ml 60 500 g

1% 1%

Oct-09 Oct-09

(B) (B)

1.04

10 g

Oct-09

Dal Orion

556.59

120

SEVOFLURANE Liq 250 ml bottle ............................Baxter 1,230.00 Note – Abbott Sevorane to be delisted 1 November 2009. SODIUM HYALURONATE Opthalmic inj 4 mg per ml ...............Healon GV Opthalmic soln 10 mg per ml ..........Healon Clear 50.00 35.00

Nov-09

Sevorane

1 0.85 ml 60

1% 1%

Oct-09 Oct-09

(B) Provisc

TAMOXIFEN CITRATE Tab 20 mg......................................Tamoxifen Sandoz 6.66

Section H changes to Part IV

Effective 1 August 2009

PEGFILGRASTIM Inj 6 mg per 0.6 ml prefilled syringe Indefinite supply for any appropriate indication for the management of patients with cancer.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A Aciclovir ............................................................ 29 Aerrane .............................................................. 32 Alpha-Bromocriptine .......................................... 28 Anastrozole-DP .................................................. 20 Andriol Testocaps .............................................. 17 Apo-Bromocriptine ............................................. 17 Apo-Clopidogrel ........................................... 23, 29 Arrow-Azithromycin ........................................... 20 Arrow-Clopidogrel .................................. 17, 23, 29 Atenolol ............................................................. 31 Azithromycin ...................................................... 20 Azol ............................................................. 23, 29 B Baclofen ............................................................ 29 Baraclude .................................................... 20, 32 B-D Micro-Fine................................................... 23 Betadine............................................................. 31 Betadine Skin Prep ....................................... 23, 31 Betahistine dihydrochloride........................... 23, 29 Betaloc CR ............................................. 18, 23, 30 Blood glucose diagnostic test meter ................... 29 Blood glucose diagnostic test strip ..................... 25 Bromocriptine mesylate................................ 17, 28 Budesonide .................................................. 23, 29 Butacort Aqueous ........................................ 23, 29 C Cancidas............................................................ 29 Caspofungin....................................................... 29 Chlorhexidine ..................................................... 29 Clexane .............................................................. 32 Clonazepam ....................................................... 29 Clopidogrel ............................................ 17, 23, 29 Clopine .............................................................. 31 Clopixol........................................................ 17, 31 Clozapine ........................................................... 31 Cyclosporin A .................................................... 20 D Danazol........................................................ 23, 29 Dasatinib............................................................ 32 Desflurane ......................................................... 32 Diabetic enteral feed 1kcal/ml ............................. 26 Diazepam..................................................... 28, 30 Diclocil .............................................................. 25 Dicloxacillin........................................................ 25 DM Ject ....................................................... 17, 30 DP-Anastrozole .................................................. 20 D-Zol ........................................................... 23, 29 E Enoxaparin sodium............................................. 32 Entecavir ...................................................... 20, 32 Epirubicin........................................................... 32 Epirubicin Ebewe................................................ 32 Ethinyloestradiol with gestodene ......................... 25 Ethinyloestradiol with levonorgestrel ................... 25 F Fentanyl citrate................................................... 32 Fleet Glycerin Suppositories ............................... 25 Flucon.......................................................... 23, 27 Fluorometholone .......................................... 23, 27 Flutamide ..................................................... 23, 30 Flutamin ....................................................... 23, 30 Fortimel ............................................................. 23 G Gabapentin ........................................................ 32 Gluten free pasta ................................................ 28 Glycerol ............................................................. 25 Goserelin acetate ............................................... 19 H Habitrol .............................................................. 18 Healon Clear ...................................................... 33 Healon GV.......................................................... 33 healthE Fatty Cream ........................................... 33 Hydroxyethyl starch 130/0.4 .............................. 30 I Insulin pen needles................................. 17, 23, 30 Insulin syringes, disposable with attached needle ......................................... 17, 30 Invirase .............................................................. 33 Isoflurane ........................................................... 32 Isotretinoin ................................................... 17, 30 K Kenacomb ......................................................... 25 Kenacort-A......................................................... 25 Ketone blood beta-ketone electrodes .................. 18 L Labetalol ............................................................ 25 Lamotrigine.................................................. 28, 30 Leuprorelin......................................................... 33 Lignocaine ......................................................... 30 Lioresal Intrathecal ............................................. 29 Lucrin Depot PDS............................................... 33 M Metoprolol succinate .............................. 18, 23, 30 Minulet 28.......................................................... 25 Mogine ........................................................ 28, 30 N Neoral ................................................................ 20 Nevirapine .......................................................... 33 Nicotine ............................................................. 18 Nicotinell ............................................................ 18 Nupentin ............................................................ 32 O Oil in water emulsion .......................................... 33

Index

Pharmaceuticals and brands Ondansetron hydrochloride................................. 31 Optium 10 second test ....................................... 25 Optium Blood Ketone Test Strips ........................ 18 Optium Xceed .................................................... 29 Oral feed 1kcal/ml .............................................. 23 Oratane ........................................................ 17, 30 Orgran ............................................................... 28 P Pacific Atenolol .................................................. 31 Paclitaxel ..................................................... 28, 31 Paclitaxel Ebewe .......................................... 28, 31 Paraffin .............................................................. 33 Parnate S29 ....................................................... 20 Pegatron Combination Therapy ........................... 27 Pegfilgrastim ...................................................... 33 Pegylated interferon alpha-2b with ribavirin ......... 27 Pilocarpine ......................................................... 28 Pilocarpine oral liquid ......................................... 22 Pilopt ................................................................. 28 Plavix ................................................................. 23 Povidone iodine ........................................... 23, 31 Pro-Pam ...................................................... 28, 30 R Requip ............................................................... 26 Requip Follow-on Pack....................................... 26 Requip Starter Pack............................................ 26 Resource Diabetic TF RTH.................................. 26 Rivotril ............................................................... 29 Ropinirole hydrochloride..................................... 26 S Saquinavir .......................................................... 33 SC Profi-Fine................................................ 17, 30 Sevoflurane ........................................................ 33 Sodium hyaluronate ........................................... 33 Sprycel .............................................................. 32 Suprane ............................................................. 32 T Tamoxifen citrate................................................ 33 Tamoxifen Sandoz.............................................. 33 Testosterone undecanoate.................................. 17 Trandate ............................................................ 25 Tranylcypromine sulphate .................................. 20 Triamcinolone acetonide .................................... 25 Triamcinolone acetonide with gramicidin, neomycin and nystatin .................................... 25 Trimipramine maleate ......................................... 27 Triphasil 28 ........................................................ 25 Tripress ............................................................. 27 V Vergo 16 ...................................................... 23, 29 Vinorelbine ......................................................... 23 Viramune ........................................................... 33 Viramune Suspension ........................................ 33 Voluven.............................................................. 30 X Xylocaine Jelly ................................................... 30 Z Zofran ................................................................ 31 Zoladex .............................................................. 19

Pharmaceutical Management Agency Level 9, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

PHARMAC is the Government agency responsible for deciding which medicines are subsidised for New Zealanders. It manages spending on pharmaceuticals for the District Health Boards, and ensures that a comprehensive list of medicines (the Pharmaceutical Schedule) is subsidised for New Zealanders, and that the list of medicines continues to grow to meet the needs of patients.

Metadata

Title

Schedule Update - effective 1 September 2009

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 September 2009 Section H cumulative for August and September 2009 Contents Summary of PHARMAC decisions effective 1 September 2009 …. 3 Nicotine replacement therapy – available on prescription ….. 5…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.